Skip to main content
SpringerLink
Log in

Dosage optimisation difficult but crucial to optimal management of epilepsy

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nicolson A, Leach JP Future prospects for the drug treatment of epilepsy. CNS Drugs 2001; 15(12): 955–68

    Article  PubMed  CAS  Google Scholar 

  2. Heaney DC, Sander JWAS. Ensuring appropriate care in epilepsy: an overview of epidemiological and cost of illness considerations. Dis Manage Health Outcomes 1998 Dec; 4(6): 303–13

    Article  Google Scholar 

  3. Manford M, Hart Y, Sander JWAS, et al. The National General Practice Study of Epilepsy: the syndromic classification of the International League Against Epilepsy applied to epilepsy in a general population. Arch Neurol 1992; 49: 801–8

    Article  PubMed  CAS  Google Scholar 

  4. Perucca E, Dulac O, Shorvon S, et al. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001; 15(8): 609–21

    Article  PubMed  CAS  Google Scholar 

  5. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000; 356: 323–9

    Article  PubMed  CAS  Google Scholar 

  6. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168–75

    Article  PubMed  CAS  Google Scholar 

  7. Brodie MJ, Kwan P. The Star Systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001; 15(1): 1–12

    Article  PubMed  CAS  Google Scholar 

  8. Leach JP. Antiepileptic drugs: safety in numbers? Seizure 2000; 9: 170–8

    Article  PubMed  CAS  Google Scholar 

  9. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314–9

    Article  PubMed  CAS  Google Scholar 

  10. Devinsky O. Patients with refractory seizures. N Engl J Med 1999; 340: 1565–70

    Article  PubMed  CAS  Google Scholar 

  11. Perucca E. Is there a role for therapeutic monitoring of new anticonvulsants? Clin Pharmacokinet 2000 Mar; 38(3): 191–204

    Article  PubMed  CAS  Google Scholar 

  12. Koch-Weser J. The serum level approach to individualization of drug dosage. Eur J Clin Pharmacol 1975 Oct 10; 9(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  13. Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs 1998; 10: 171–9

    Article  Google Scholar 

  14. Lund L. Anticonvulsant effects of diphenylhydantoin relative to plasma levels: a prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol 1974 Nov; 31(5): 289–94

    Article  PubMed  CAS  Google Scholar 

  15. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000 Sep; 41(2): 107–39

    Article  PubMed  CAS  Google Scholar 

  16. Yuen AW, Land G, Weatherley B, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992 May; 33(5): 511–3

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dosage optimisation difficult but crucial to optimal management of epilepsy. Drugs Ther. Perspect 18, 13–16 (2002). https://doi.org/10.2165/00042310-200218070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218070-00005

Keywords

Search

Navigation